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In early August 2000, infectious disease specialists in
hospitals in central Israel noted an increasing number of
elderly patients admitted for encephalitis. By mid-August,
when several blood and cerebrospinal fluid (CSF) samples
tested positive for antibodies for West Nile (WN) virus, an
outbreak was suspected. Eventually a WN fever epidemic
that affected the entire country was recognized.
This article outlines the epidemiologic aspects of this WN
fever epidemic; Chowers et al. (1) details the clinical
characteristics. These are the first in-depth descriptions of an
outbreak caused by WN virus involving an entire country.
Methods
Serologic studies from blood and CSF were performed by
one facility, the Central Virology Laboratory, Public Health
Services, Israel Ministry of Health, at the Chaim Sheba
Medical Center, Tel Hashomer. From August 1 to October 31,
2000, this  laboratory reported 417 serologically confirmed
cases of WN fever to the Epidemiology Department of the
Israel Ministry of Health. These patients are the focus of
our study.
Basic demographic data, date of disease onset, and the
patients’ final outcome (alive or dead) were available from the
files of the Department of Epidemiology, Israel Ministry of
Health, and health district offices around the country. From
early September 2000, infectious disease specialists in
hospitals throughout Israel were asked to complete a detailed
questionnaire on clinical, epidemiologic, and laboratory data
for patients with WN virus at their hospitals. Information on
the clinical presentation of the patients at ambulatory
settings was obtained from the health district offices.
Data on the Israeli population by age group, geographic
distribution, and type of locality were retrieved from the
Israeli Central Bureau of Statistics (2). Israel is divided into
six major geographic districts (Jerusalem, Northern, Haifa,
Center, Tel-Aviv, Southern), as well as the Judea, Samaria,
and Gaza areas. The permanently inhabited places in Israel
are divided into urban (>2,000 population) and rural (<2,000,
even if not agricultural) localities.
Diagnosis of WN fever was based on immunoglobulin M
(IgM)-capture enzyme-linked immunosorbent assay (MAC-
ELISA) in serum or CSF samples of patients. The assay,
which was developed in the Central Virology Laboratory
during 1999-2000, includes the following steps: a) binding of
anti-human IgM to the ELISA plate; b) incubation with the
patient’s serum or CSF sample (dilutions of 1:100 and 1:2,000
for serum and 1:10 and 1:100 for CSF); c) incubation with WN
virus antigen prepared from Vero cells infected with an Israeli
gull isolate from 1999 (Banet C, manuscript in prep.);
d) incubation with a mouse anti-flavivirus monoclonal
antibody (JCU/KUN/2B2, cat. no. 01-031-02, TropBio Pty
Queensland, Australia); and e) incubation with peroxidase-
conjugated goat anti-mouse antibody (cat. no. 115-035-071,
Jackson ImmunoResearch Laboratories, West Grove, PA) and
substrate. Cross-reactivity with other flaviviruses was not
thoroughly evaluated; however, no other endemic cross-
reacting flavivirus is known to infect humans in Israel. A
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From August 1 to October 31, 2000, 417 cases of West Nile (WN) fever were
serologically confirmed throughout Israel; 326 (78%) were hospitalized patients.
Cases were distributed throughout the country; the highest incidence was in
central Israel, the most populated part. Men and women were equally affected,
and their mean age was 54±23.8 years (range 6 months to 95 years). Incidence
per 1,000 population increased from 0.01 in the 1st decade of life to 0.87 in the
9th decade. There were 35 deaths (case-fatality rate 8.4%), all in patients >50
years of age. Age-specific case-fatality rate increased with age. Central nervous
system involvement occurred in 170 (73%) of 233 hospitalized patients. The
countrywide spread, number of hospitalizations, severity of the disease, and
high death rate contrast with previously reported outbreaks in Israel.687 Vol. 7, No. 4, July–August 2001 Emerging Infectious Diseases
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patient with a positive MAC-ELISA from serum or CSF was
considered to have a serologically confirmed case of WN fever.
Serologic studies for WN virus were not routine in Israel
before 2000; this changed in early August 2000, when the first
cases of WN fever were documented. Blood or CSF samples for
serologic studies were submitted by primary physicians or
infectious disease consultants caring for hospitalized
patients, based on clinical suspicion. Although not
encouraged by the Israeli health authorities, blood samples
for serologic studies were also submitted by primary
physicians caring for ambulatory patients.
Contingency tables were tested for statistical signifi-
cance by the chi-square test. Continuous variables were
tested by the Student t test. SAS software (SAS Inc., Cary,
NC) was used for data analysis.
Results
Geographic Distribution
From August 1 to October 31, 2000, 417 cases of WN fever
were confirmed by the Central Virology Laboratory. Patients
were distributed throughout 113 localities in Israel. The most
populated localities in the coastal plains of Israel were the
most heavily affected, followed by the northern parts. The
Negev and Jerusalem areas were the least heavily affected.
No cases of WN virus fever were reported from the Judea,
Samaria, and Gaza areas. Incidence rates by geographic
district are given in Figure 1.
Three hundred thirty-nine (81.5%) patients resided in
urban localities, and 77 (18.5%) in rural localities;
however, the incidence of WN virus infection was 2.3-fold
higher in rural localities (0.14 cases per 1,000 population)
than in urban areas (0.06 cases per 1,000 population,
p<0.001).
The Epidemic Curve
The exact date of disease onset was available for 379
(91%) patients with serologically confirmed WN fever.
According to these data, the outbreak started at the end of
July-early August, 2000, peaked in the second week of
September, and abated by the end of October (Figure 2). The
main wave of the epidemic started in the central parts of
Israel (Center and Tel-Aviv districts), where 41% (2.5 million)
of the Israeli population resides. One week later, the epidemic
spread to the northern parts of Israel (Haifa and Northern
districts), but peaked at the same time as in the central areas.
A much smaller wave occurred in the south of Israel
(Southern District): it started at the end of August and peaked
at the end of September, 2 weeks later than the rest of the
country (Figure 3).
Figure 1. Incidence of West Nile fever infection by district, Israel,
2000.
Figure 2. Serologically confirmed West Nile fever cases by week of
disease onset, Israel, 2000.
Figure 3. Distribution of West Nile fever cases by week of onset and
geographic district, Israel, 2000.688 Emerging Infectious Diseases Vol. 7, No. 4, July–August 2001
West Nile Virus
Patient Characteristics and Outcome
Of the 417 patients with serologically confirmed WN
virus infection, 209 (50.1%) were female; age ranged from 6
months to 95 years (mean 54.5 ± 23.8 years, median 57). Only
6% (25 patients) were <14 years; 46% (192 patients) were >60
years. The overall incidence per 1,000 population was 0.07;
incidence increased dramatically with age, from 0.01 in the
1st decade of life to 0.48 and 0.87 in the 9th and 10th decades,
respectively (Figure 4). Notably, 15 (11.9%) of 126
hospitalized patients who were >60 years of age were
residents of nursing homes.
Three hundred twenty-six patients (78%) were hospital-
ized in 20 hospitals throughout Israel, and 91 (22%) were
diagnosed in ambulatory settings. Ambulatory patients were
significantly younger than hospitalized patients (mean age 44
± 17.8 years vs. 57.4 ± 24.3 years, respectively, p<0.0001).
Clinical data were available for 233 (71%) of the 326
hospitalized patients and 37 (52%) of the 71 ambulatory
patients. While 170 (73%) of the hospitalized patients had
central nervous system (CNS) involvement (encephalitis 133
patients, meningitis 37), only 3 (8%) of the ambulatory
patients had mild encephalitis. Further details are presented
in a companion article (1).
Thirty-five (10.7%) of the 326 patients hospitalized with
WN fever died during hospitalization (33 patients) or within 1
week after discharge (2 patients). None of the 91 ambulatory
patients died. The case-fatality rate for all 417 patients was
8.4% (35 of 417 patients); this rate did not differ significantly
between females (19 [9.1%] of 209) and males (16 [7.7%] of
208). The mean age of the patients who died was 79.1 ± 9.2
years (median 80), the youngest being 54 and the oldest 95
years old. In comparison, the mean age of the patients who
survived was 52.2± 23.3 years (p <0.0001).
The case-fatality rate increased dramatically with age
(Figure 4). Among all patients ages >60 years, the case-
fatality rate was 17.7% (34 of 192). Predictors of death in
hospitalized patients are discussed in a companion article (1).
Discussion
WN fever is endemic in Israel (3-13); however, the impact
of the 2000 outbreak was unprecedented. It involved all age
groups, affected all parts of the country, resulted in the
hospitalization of 326 patients within a 3-month period, and
claimed the lives of 35 persons. The most prominent feature of
this outbreak was an exceptionally high rate of CNS illness.
Israeli researchers in the 1950s were the first to
characterize the clinical presentation of WN fever, but by the
end of the 20th century, WN virus infection was an almost
forgotten disease in Israel. Moreover, previous reports did not
prepare the infectious disease community and health
authorities for the scope, magnitude, and severity of the
recent outbreak (14). Infectious disease experts quickly
responded to the outbreak by arousing public opinion,
enforcing preventive measures, exploring novel therapies (15,
Huminer D, et al., unpub. data), and collaborating to form a
detailed national clinical database.
Several WN fever outbreaks were reported from Israel in
the 1950s and one in 1980 (Table 1) (4-12); most patients were
young soldiers in training, who contracted the infection in
army camps. Many of them were transferred to military
hospitals in accordance with army routines (not necessarily
because their illness was severe). The most common
manifestation of WN fever in soldiers was an acute febrile
illness with headache; a generalized rash occurred in
approximately one third. CNS involvement was unusual, and
the outcome was excellent.
Information about WN fever in the civilian population is
more limited. In 1951, an outbreak occurred in a small
agricultural settlement (Maayan Zvi) south of Haifa; 41% of
its 303 inhabitants became ill (5,6). All age groups were
affected, but only one child (0.8%) had mild aseptic
meningitis, and no deaths were reported. Most adults in the
settlement were 20 to 35 years old. Another report described
a WN fever outbreak among 65 civilians residing in the
Hadera area in 1957 (11); 2 patients (a child and an adult) had
encephalitis (3.1%), which resolved without sequelae. No
deaths were reported.
Standing out among these reports was a description of
WN virus infection in 49 elderly patients, ages 66 to 86 years
(mean 70 years), who were residents of four nursing homes in
the Hadera area, the center of the 1957 epidemic (11).
Encephalitis developed in one third of these patients and four
died (8.1%). Serologic tests for WN virus were positive in 53%
of the 49 patients (and 75% of those with encephalitis), and
autopsy was compatible with encephalitis in one of four fatal
cases. This was the first time that infection caused by WN
virus was associated with severe encephalitis and death.
Some researchers believe (8,11) that a large outbreak of
febrile illness accompanied by rash that occurred in 1941 (4),
before the state of Israel was established, was also due to WN
virus. Obviously, this could not be confirmed at the time, since
the WN virus was a newly discovered virus (16) with unknown
epidemiology, and diagnostic tests were not yet available.
However, the clinical characteristics and time of year support
the diagnosis of WN virus infection. An estimated 500 people
in the Central and Tel-Aviv districts became ill. If one
assumes that the diagnosis was correct, this was probably the
largest outbreak in Israel, considering that the total
population at that time was only 449,000 (2). In that outbreak
no CNS involvement and no deaths were reported.
Figure 4. Incidence and deaths from West Nile fever by age group,
Israel, 2000.689 Vol. 7, No. 4, July–August 2001 Emerging Infectious Diseases
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The time of year in which WN fever outbreaks appear in
Israel has remained almost constant for the last 5 decades.
The previously reported outbreaks (4,6), as well as the recent
one, occurred between late July and early October. In
comparison, the 1996 epidemic in southeast Romania ended
by mid-September (17), and the 1999 epidemic in New York
abated by the end of September (18-20).
The severity and scope of the year 2000 outbreak in Israel
can be better appreciated when compared with other WN
virus outbreaks worldwide in the last decade (Table 2) (17,20-
24). The Israeli outbreak most resembles the Romanian
outbreak in 1996 (17), although both the incidence (7 vs. 4 per
100,000 population, respectively) and the death rate of
hospitalized patients (10.7% vs 4.3%, respectively) were
higher in Israel.
The vectors of WN virus in Israel are mosquitoes of the
Culex species (Cx. pipiens and Cx. perexiguus) (25,26). The
reservoir is wild birds, including pigeons, storks, and crows
(25,27,28). In 1997, the virus infected the commercial geese
population in Israel (Banet C, manuscript in prep.), a
phenomenon that has not been previously described. This
resulted in neurologic illness and death in the affected flocks.
During 1998 and 1999, 18% to 20% of the 60 flocks in the
country were affected, and approximately 5,000 geese died or
were killed (O. Nir Markusfeld, pers. comm.). The virus was
also isolated from live and dead horses (Banet C, manuscript
in prep; 28).
Human cases were not reported to the Ministry of Health
during the 1990s until 1999, when three cases were
diagnosed: a young woman with encephalitis who had fully
recovered and two elderly patients who died of the disease
(29,30). In late 1999 and the first quarter of 2000, the Central
Virology Laboratory conducted a serologic survey in Eilot
region, a rural area located in the Southern District. This
survey revealed two additional cases of acute encephalitis and
a 22% rate of IgM seropositivity to WN virus (E. Mendelson,
pers. comm.).
A high degree of similarity (>99.8%) was found between
the virus isolated from the brain of a dead Israeli goose in
1998 and the U.S. WN virus isolates from the 1999 epidemic
(31). In the same study, an earlier Israeli WN virus isolate
from 1952 was found to be phylogenetically closer to the 1996
Romanian isolate. More recent studies have also indicated
that two phylogenetically distinct WN virus strains are
cocirculating among humans (32) as well as avians and
equines in Israel (Banet C, manuscript in prep.).
WN virus has reemerged in Israel with renewed virulence
and vigor. One possible explanation is the waning of
immunity among the Israeli population. Serologic studies
from the 1950s in a small number of soldiers residing in
epidemic areas revealed a 50% seropositivity during the
outbreak season and a 14% seropositivity off-season (10).
Other studies revealed 48% to 73% seropositivity in endemic
Table 1. Reported outbreaks caused by West Nile virus in Israel
   No.      CNS  Reported
Year (Ref)       Area Type of locality studied Age  involvement    deaths        Documentation
1941 (4) Center & Tel- Urban & rural 500 All ages None None None
  Aviv
1951 (5,6) Haifa Agricultural 123 All ages Meningitis None Virus isolate  (1/123, 0.8%)
  settlement   (1/123, 0.8%)   Serology (14/26, 54%)
1950 (7) Hadera and Army camps and 105 17-40 y Nuchal rigidity None Virus isolate  (9/50, 18%)
  coastal plain   communal   (“a few cases”)   Serology (18/24, 75%)
  settlement
1950-53 (8) Militarya Army camps 400 17-23 y Meningitis None NA
  hospital   (1/400, 0.3%)
1953 (9) Tel Hashomer Army camps 70 18-20 y None None Virus isolate (13/70, 18%)
  Hospitala   Serology (50/70, 68%)
1953-1954 (10) Center and Army camps 300 Young N/A None Virus isolate (40/205, 20%)
  North Israel   adults   Serology (66/151/ 57%)
1957 (11) Hadera area Army camps 300 18-28 y Encephalitis None Virus isolate (8/50, 40%)
  (1/300, 0.3%)   Serology (139/154, 88%)
Urban & rural 65 All ages Encephalitis None Serology (23/50, 46%)
  (2/56, 3.1%)
Nursing homes 49 66-86 y Encephalitis 4/49, 8.2% Serology (53%) (in patients
  16/49 (33%)   with encephalitis: 9/12, 75%)
1980 (12) Negev  Desert Army camps 32 18 y Meningitis None Serology (10/11, 91%)
  (1/32, 3.1%)
Nuchal rigidity
  (3/32, 9.3%)
2000 (PR) Country-wide Urban and rural 417 0.5-95 Encephalitis 35/417, 8.4% Serology (417/417, 100%)
  (135/256, 51%)
  (35/265, 13%)
aSoldiers were transferred to military hospitals according to army routines, not necessarily because of severe illness.
CNS = central nervous system; y = year; PR = present report.
Table 2. Reported deaths in WN virus outbreaks during the last decade
          No.
         cases    Deaths
Year Location          studied    (%) Reference
1994 Algeria 13 13.3a (21)
1996 South Romania 393 4.3 (17)
1999 New York 61 11.5 (20,22)
1999 South Russia 1,000 4.0 (23)
2000 New York, New Jersey 19b 10.5 (24)
2000 Israel 417 8.4 Present report
aPatients were mainly young children.
bHospitalized patients only.690 Emerging Infectious Diseases Vol. 7, No. 4, July–August 2001
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areas, compared with 7% to 12% in nonendemic areas (13).
The only large-scale study was published in 1999 by Cohen et
al. (3), who tested stored sera of 1,060 soldiers, 18 to 55 years
of age, which were collected between 1982 and 1989.
Seroprevalence for WN virus was found to increase with age:
from 7% in the 18- to 20-year age group to 10.5% in the 21- to
30-year age group, and as high as 41.9% for people ages 40 to
55. While revealing a high level of background immunity,
these results do not support waning of seropositivity to WN
virus with age.
The elderly population in Israel has almost doubled since
the 1950s. In 1951, the proportion of patients >60 years was
6.8% (33); it increased to 13.2% in 1998, according to the most
recent census (2). Forty-six percent of the WN fever cases and
97% of the fatal cases in the 2000 epidemic occurred in this
age group. Unfortunately, no data are available on
seroprevalence in the elderly in Israel. Pending results of a
recently performed large serologic study in the general
population, including nursing homes, may shed more light on
this issue.
The changing face of WN virus epidemiology is not unique
to Israel, but is a global phenomenon (34,35). Increased CNS
invasiveness and a high case-fatality rate were also features
of the outbreaks in southeast Romania and New York (17-
20,36,37). This apparent increase in virulence had been also
noted among birds in New York City (38) and commercial
geese in Israel (Banet C, manuscript in prep.), who became
sick and died as a result of WN infection. As more data are
accumulating, it is tempting to speculate on a possible
alteration in the virulence of WN virus. The altered strain
may have been introduced into local avian populations by
migratory birds, and then into humans and equines (Banet C,
manuscript in prep.; 39).
The potential for causing large-scale outbreaks, with
substantial illness and death, and the spread of WN virus
across the globe call for international cooperation in
developing effective vaccines and planning innovative
strategies for mosquito control.
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